288 related articles for article (PubMed ID: 19188092)
1. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus.
Parameswaran R; Ben David H; Sharabi A; Zinger H; Mozes E
Clin Immunol; 2009 May; 131(2):223-32. PubMed ID: 19188092
[TBL] [Abstract][Full Text] [Related]
2. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
3. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
[TBL] [Abstract][Full Text] [Related]
4. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
5. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
6. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
[TBL] [Abstract][Full Text] [Related]
7. Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells.
Fletcher CA; Sutherland AP; Groom JR; Batten ML; Ng LG; Gommerman J; Mackay F
Eur J Immunol; 2006 Sep; 36(9):2504-14. PubMed ID: 16906535
[TBL] [Abstract][Full Text] [Related]
8. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
10. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
[TBL] [Abstract][Full Text] [Related]
11. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy.
Yoshimoto K; Takahashi Y; Ogasawara M; Setoyama Y; Suzuki K; Tsuzaka K; Abe T; Takeuchi T
Int Immunol; 2006 Jul; 18(7):1189-96. PubMed ID: 16740602
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis.
Sharabi A; Haviv A; Zinger H; Dayan M; Mozes E
Clin Immunol; 2006 May; 119(2):146-55. PubMed ID: 16503419
[TBL] [Abstract][Full Text] [Related]
13. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease.
Enzler T; Bonizzi G; Silverman GJ; Otero DC; Widhopf GF; Anzelon-Mills A; Rickert RC; Karin M
Immunity; 2006 Sep; 25(3):403-15. PubMed ID: 16973390
[TBL] [Abstract][Full Text] [Related]
14. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.
Mackay F; Silveira PA; Brink R
Curr Opin Immunol; 2007 Jun; 19(3):327-36. PubMed ID: 17433868
[TBL] [Abstract][Full Text] [Related]
15. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells.
Yang M; Sun L; Wang S; Ko KH; Xu H; Zheng BJ; Cao X; Lu L
J Immunol; 2010 Apr; 184(7):3321-5. PubMed ID: 20208006
[TBL] [Abstract][Full Text] [Related]
16. KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, is a novel compound to be effective on mouse systemic lupus erythematosus.
Lee GH; Oh JM; Kim HS; Yoon WK; Yi KY; Yang Y; Han SH; Lee S; Moon EY
Eur J Pharmacol; 2011 Oct; 668(3):459-66. PubMed ID: 21827747
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
[TBL] [Abstract][Full Text] [Related]
18. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus.
Chu VT; Enghard P; Schürer S; Steinhauser G; Rudolph B; Riemekasten G; Berek C
Arthritis Rheum; 2009 Jul; 60(7):2083-93. PubMed ID: 19565488
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.
Krumbholz M; Faber H; Steinmeyer F; Hoffmann LA; Kümpfel T; Pellkofer H; Derfuss T; Ionescu C; Starck M; Hafner C; Hohlfeld R; Meinl E
Brain; 2008 Jun; 131(Pt 6):1455-63. PubMed ID: 18474519
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
